CN110511152B - Preparation method of voglibose impurity I hydrochloride - Google Patents
Preparation method of voglibose impurity I hydrochloride Download PDFInfo
- Publication number
- CN110511152B CN110511152B CN201910880204.1A CN201910880204A CN110511152B CN 110511152 B CN110511152 B CN 110511152B CN 201910880204 A CN201910880204 A CN 201910880204A CN 110511152 B CN110511152 B CN 110511152B
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- voglibose
- impurity
- hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 title claims abstract description 65
- 229960001729 voglibose Drugs 0.000 title claims abstract description 63
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title claims abstract description 55
- 239000012535 impurity Substances 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 7
- 125000006239 protecting group Chemical group 0.000 claims abstract description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 6
- HQVLYZQFGNHUQT-UHFFFAOYSA-N 2-phenylmethoxy-5-(phenylmethoxymethyl)cyclohexan-1-one Chemical compound C(C1=CC=CC=C1)OC1C(CC(CC1)COCC1=CC=CC=C1)=O HQVLYZQFGNHUQT-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000006722 reduction reaction Methods 0.000 claims abstract description 5
- 238000005576 amination reaction Methods 0.000 claims abstract description 4
- 238000009833 condensation Methods 0.000 claims abstract description 4
- 230000005494 condensation Effects 0.000 claims abstract description 4
- 150000002924 oxiranes Chemical class 0.000 claims abstract description 4
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 claims abstract description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 238000010511 deprotection reaction Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 4
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 claims description 4
- 229940073608 benzyl chloride Drugs 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 239000007789 gas Substances 0.000 claims description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 4
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 3
- 239000003638 chemical reducing agent Substances 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000001514 detection method Methods 0.000 description 8
- -1 tert-butyl ((2S) -3-hydroxy-2- (((2S, 3R, 4S,5S) -2,3, 4-tris (benzyloxy) -5- ((benzyloxy) methyl) -5-hydroxycyclohexyl) amino) propyl) carbamic acid tert-butyl ester Chemical compound 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 150000001793 charged compounds Chemical class 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical group C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- ZBBGKXNNTNBRBH-LURJTMIESA-N tert-butyl n-[[(2s)-oxiran-2-yl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NC[C@H]1CO1 ZBBGKXNNTNBRBH-LURJTMIESA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a preparation method of voglibose impurity I hydrochloride, which comprises the following steps: performing epoxide amination on (S) - (ethylene oxide methyl) tert-butyl carbamate and tetrabenzylvaliolamine to obtain a compound shown in a formula III; carrying out benzyl protection on hydroxyl of the compound in the formula III to obtain a compound in a formula IV; deprotecting the amino protecting group of the compound of formula IV to obtain a compound of formula V; the compound of the formula V and (2R,2S,4S,5S) -5-hydroxy-2, 3, 4-tri (benzyloxy) -5- [ (benzyloxy) methyl ] -cyclohexanone undergo a condensation reduction reaction to obtain the compound of the formula VI. The preparation method of the impurity I hydrochloride of the voglibose, provided by the invention, has a simple process flow, fills the gap in the existing technology for preparing the impurity I of the voglibose, can be used for qualitative and quantitative researches on the impurity in the production of the voglibose, and can improve the quality standard of the voglibose, thereby improving the medication safety of the voglibose.
Description
Technical Field
The invention relates to the technical field of medicines, and particularly relates to a preparation method of voglibose impurity I hydrochloride.
Background
Voglibose, chemical name (+) -1L- [1 (hydroxy), 2,4,5/3] -5- [ 2-hydroxy-1- (hydroxymethyl) ethyl ] amino-1- (hydroxymethyl) -1,2,3, 4-cyclohexanetetraol, CAS:83480-29-9, has a chemical structure shown in formula:
voglibose was first developed by Takeda, japan, first in 1994 under the trade name "Basen", in korea in 1998, and in china in 1999, and is used for the treatment of postprandial blood glucose elevation in diabetes. Voglibose entered the catalog of national basic medical insurance, industry and commerce insurance and fertility insurance drugs in 2009. At present, voglibose is widely used for preventing and treating type I and type II diabetes and combined medicines. Voglibose has no stimulation to insulin secretion compared with sulfonylureas, has the effect of moderating but not inhibiting the digestion and absorption of saccharides compared with biguanides, and has less dosage and less side effects such as abdominal distension compared with acarbose.
The quality standards for voglibose are documented in the japanese pharmacopoeia JP17 and the korean pharmacopoeia 10 th edition, and currently the chinese pharmacopoeia is discussed. Structures that may contain impurities are not specified in the japanese pharmacopoeia JP17 and the korean pharmacopoeia 10 th edition, but there are three impurities that specify retention times of about 1.7, 2.0 and 2.3 relative to voglibose. The structures of voglibose, which may contain three impurities, are clearly indicated in japanese IF documents of voglibose and the first public edition of the "chinese pharmacopoeia" 2020. The structural formula is as follows:
the three impurities are subjected to system applicability experiments and impurity control in a mixed contrast mode, the impurity I and the impurity II are isomers, and at present, no report about preparation of the impurity I exists. The impurity I of the voglibose is an impurity concerned in a voglibose quality standard, and has great significance for the research of substances related to the voglibose, so that the method for preparing the impurity I of the voglibose is significant.
Disclosure of Invention
The invention aims to disclose a preparation method of voglibose impurity I hydrochloride, which has simple process flow and fills the blank of the prior art for preparing the voglibose impurity I, and the prepared voglibose impurity I hydrochloride can be used for qualitative and quantitative research on impurities in the production of voglibose, can improve the quality standard of the voglibose, and thus improves the medication safety of the voglibose.
In order to achieve the aim, the invention provides a preparation method of voglibose impurity I hydrochloride, which comprises the following steps:
the method comprises the following steps: performing epoxide amination on (S) - (ethylene oxide methyl) tert-butyl carbamate and tetrabenzylvaliolamine to obtain a compound shown in a formula III;
step two: carrying out benzyl protection on hydroxyl of the compound in the formula III to obtain a compound in a formula IV;
step three: deprotecting the amino protecting group of the compound of formula IV to obtain a compound of formula V;
step four: carrying out condensation reduction reaction on the compound shown in the formula V and (2R,2S,4S,5S) -5-hydroxy-2, 3, 4-tri (benzyloxy) -5- [ (benzyloxy) methyl ] -cyclohexanone to obtain a compound shown in a formula VI;
step five: deprotection of a hydroxyl protecting group of the compound shown in the formula VI and salification are carried out to obtain high-purity voglibose impurity I hydrochloride; the overall reaction flow is:
in some embodiments, in step two, the hydroxy group of the compound of formula iii is benzyl protected under basic conditions to provide the compound of formula iv.
In some embodiments, in step two, the base used is potassium hydroxide or sodium hydroxide.
In some embodiments, in step two, the hydroxy protecting reagent used is benzyl chloride or benzyl bromide.
In some embodiments, in step three, the amino protecting group of the compound of formula iv is deprotected under the action of an acid to provide the compound of formula v.
In some embodiments, in step three, the acid used is trifluoroacetic acid or hydrochloric acid.
In some embodiments, in step four, the reducing agent used is sodium cyanoborohydride.
In some embodiments, in step five, the hydroxyl protecting group of the compound of formula vi is deprotected by catalytic hydrogenation to form a salt, resulting in high purity voglibose impurity I hydrochloride.
In some embodiments, in step five, the catalyst used is palladium on carbon.
In some embodiments, in step five, the salt former reagent is hydrogen chloride gas.
Compared with the prior art, the invention has the beneficial effects that: the preparation method of the impurity I hydrochloride of the voglibose, provided by the invention, has a simple process flow, fills the gap in the existing technology for preparing the impurity I of the voglibose, can be used for qualitative and quantitative researches on the impurity in the production of the voglibose, and can improve the quality standard of the voglibose, thereby improving the medication safety of the voglibose.
Drawings
FIG. 1 is a mass spectrum of voglibose impurity I hydrochloride;
FIG. 2 is a mass spectrum of voglibose impurity I hydrochloride;
FIG. 3 is a nuclear magnetic diagram (1H spectrum) of Voglibose impurity I hydrochloride.
Detailed Description
The present invention is described in detail with reference to the embodiments shown in the drawings, but it should be understood that these embodiments are not intended to limit the present invention, and those skilled in the art should understand that functional, methodological, or structural equivalents or substitutions made by these embodiments are within the scope of the present invention.
The invention discloses a preparation method of voglibose impurity I hydrochloride, which comprises the following steps:
the method specifically comprises the following steps:
the method comprises the following steps: performing epoxide amination on the (S) - (oxiranylmethyl) carbamic acid tert-butyl ester and tetrabenzylvaliolamine to obtain a compound shown in a formula III, namely tert-butyl ((2S) -3-hydroxy-2- (((2S, 3R, 4S,5S) -2,3, 4-tris (benzyloxy) -5- ((benzyloxy) methyl) -5-hydroxycyclohexyl) amino) propyl) carbamic acid tert-butyl ester;
the specific method comprises the following steps:
5.53g of tetrabenzylvaliolamine (2.77 g of tert-butyl (S) - (oxiranylmethyl) carbamate and 140ml of methanol are added into a reaction bottle, the mixture is heated and refluxed for 18 hours, the mixture is concentrated in vacuum to be dry, the residue is dissolved in toluene, the mixture is washed with water, dried by anhydrous sodium sulfate, filtered and concentrated under reduced pressure, and the residue is purified by a silica gel column to obtain 5.3g of oily matter, namely the compound shown in the formula III, wherein the molar yield is 73%.
Step two: benzyl protection of the hydroxy group of the compound of formula III gives the compound of formula IV, i.e. tert-butyl ((2S) -3-benzyloxy-2- (((2S, 3R, 4S,5S) -2,3, 4-tris (benzyloxy) -5- ((benzyloxy) methyl) -5-hydroxycyclohexyl) amino) propyl) carbamate;
in the second step, the hydroxyl of the compound in the formula III is subjected to benzyl protection under an alkaline condition to obtain a compound in the formula IV, the used alkali is potassium hydroxide or sodium hydroxide, and the used hydroxyl protecting reagent is benzyl chloride or benzyl bromide;
the specific method comprises the following steps:
adding 7.27g of the compound shown in the formula III, 1.4g of benzyl chloride, 0.1g of potassium iodide, 0.5g of sodium hydroxide and 100ml of acetonitrile into a reaction bottle, heating to reflux, filtering after the reaction is finished, washing a filter cake by using the acetonitrile, concentrating the filtrate to be dry, and purifying by using a silica gel column to obtain 5.39g of oily matter, namely the compound shown in the formula IV, wherein the molar yield is 66%.
Step three: deprotecting the amino protecting group of the compound of formula iv to obtain a compound of formula v, i.e., (1S, 2S, 3R, 4S) -5- (((S) -1-amino-3- (benzyloxy) propan-2-yl) amino) -2,3, 4-tris (benzyloxy) -1- ((benzyloxy) methyl) cyclohexanol;
in the third step, the amino protecting group of the compound shown in the formula IV is deprotected under the action of acid to obtain a compound shown in the formula V, and the acid is trifluoroacetic acid or hydrochloric acid;
the specific method comprises the following steps:
adding 8.17g of the compound shown in the formula IV and THF into a reaction bottle, stirring to dissolve the compound, dropwise adding 9ml of 4% hydrochloric acid until the reaction is completed, concentrating the solution in vacuum to remove the THF, adding dichloromethane, washing the solution with saturated sodium bicarbonate, washing the solution with water for 3 times, drying the filtrate with anhydrous sodium sulfate, and concentrating the dried filtrate under reduced pressure to obtain 5.88g of a solid, namely the compound shown in the formula V, wherein the molar yield is 87%.
Step four: carrying out condensation reduction reaction on the compound shown in the formula V and (2R,2S,4S,5S) -5-hydroxy-2, 3, 4-tri (benzyloxy) -5- [ (benzyloxy) methyl ] -cyclohexanone to obtain a compound shown in a formula VI; in the fourth step, the reducing agent is sodium cyanoborohydride;
the specific method comprises the following steps:
7.17g of the compound of the formula V, (2R,2S,4S,5S) -5-hydroxy-2, 3, 4-tris (benzyloxy) -5- [ (benzyloxy) methyl ] -cyclohexanone and 70ml of methanol are added to the reaction flask, stirred at room temperature for 1h and cooled to 0 ℃. 0.88g of sodium cyanoborohydride was added, and after completion of the reaction, methanol was removed by vacuum concentration. DCM and 2mol/L hydrochloric acid are added into the residue, and the pH is adjusted to 5-6. Separating liquid and keeping water phase. The pH was adjusted to about 8 with sodium hydroxide. The organic phase was washed with water, dried over anhydrous sodium sulfate and concentrated to dryness. Pulping with petroleum ether and crystallizing to obtain 7.01g of solid, namely the compound shown in the formula VI, with the molar yield of 55%.
Step five: deprotection and salt formation of the hydroxyl protecting group of the compound shown in the formula VI are carried out to obtain high-purity voglibose impurity I hydrochloride, namely (1S,1 'S, 2S, 2' S,3R,3 'R, 4S, 4' S,5S,5 'S) -5, 5' - ((R) -3-hydroxypropyl-1, 2-diyl) bis (azenediyl) bis ((hydroxymethyl) cyclohexyl-1, 2,3, 4-tetraol) hydrochloride;
in the fifth step, the hydroxyl protecting group of the compound shown in the formula VI is subjected to catalytic hydrogenation deprotection to form a salt, and high-purity voglibose impurity I hydrochloride is obtained; the catalyst is palladium carbon, and the salifying agent is hydrogen chloride gas.
The specific method comprises the following steps:
adding 12.5g of a compound VI, THF, 130ml of methanol and 12.5g of palladium carbon into a reaction bottle, carrying out hydrogenation reduction at room temperature under 4 pressures, continuing stirring for 1h after no hydrogen is absorbed, filtering, washing a filter cake with methanol, carrying out vacuum concentration on a filtrate, removing trace water with absolute ethyl alcohol, dissolving with ethyl acetate, and introducing hydrogen chloride gas to obtain 4.38g of white solid of voglibose impurity I hydrochloride, wherein the molar yield is 85%.
[M-2HCl+H]+＝443.27；[M-2HCl+Cl]+＝477.26；1HNMR(D2O,400MHz)＝3.9164～3.9581(dd，1H)；＝3.2656～3.3323(t，1H)；＝3.4129～3.927(bs，16H)。
The hydrochloride of voglibose impurity II can be prepared in the above manner by replacing tert-butyl (S) - (oxiranylmethyl) carbamate with tert-butyl (R) - (oxiranylmethyl) carbamate.
Performing mass spectrum detection on the prepared voglibose impurity I hydrochloride, wherein the detection result is shown in a figure 1 and a figure 2; nuclear magnetic resonance spectrum detection is carried out on the prepared voglibose impurity I hydrochloride, and the detection result is shown in figure 3.
Performing mass spectrum detection on the prepared voglibose impurity I hydrochloride, wherein the detection result is shown in a figure 1 and a figure 2; nuclear magnetic resonance spectrum detection is carried out on the prepared voglibose impurity I hydrochloride, and the detection result is shown in figure 3.
Molecular ion peaks according to FIG. 1 ([ M-2HCl + H)]+)443.27 and the molecular ion peaks of FIG. 2 ([ M-2HCl + Cl)]+)477.26 it can be seen that the detected molecular ion peak corresponds to the molecular weight of voglibose impurity I hydrochloride (514.77).
The graph analysis is carried out on the graph shown in the figure 3, wherein the total number of 25 hydrogen atoms (3.9164-3.9581, dd, 1H; (3.2656-3.3323, 1H; (3.4129-3.9277, bs, 16H); (15 active hydrogens) (11 alcoholic hydroxyl hydrogens, 2 amino hydrogens and 2 hydrogens in hydrochloric acid) are shared by the impurity I hydrochloride of the voglibose, and the graph analysis result and the molecular formula (C) of the impurity I hydrochloride of the voglibose are shared by the graph analysis result17H36Cl2N2O11) The results are consistent.
The above-listed detailed description is only a specific description of a possible embodiment of the present invention, and they are not intended to limit the scope of the present invention, and equivalent embodiments or modifications made without departing from the technical spirit of the present invention should be included in the scope of the present invention.
Furthermore, it should be understood that although the present description refers to embodiments, not every embodiment may contain only a single embodiment, and such description is for clarity only, and those skilled in the art should integrate the description, and the embodiments may be combined as appropriate to form other embodiments understood by those skilled in the art.
Claims (10)
1. The preparation method of voglibose impurity I hydrochloride is characterized by comprising the following steps:
the method comprises the following steps: performing epoxide amination on (S) - (ethylene oxide methyl) tert-butyl carbamate and tetrabenzylvaliolamine to obtain a compound shown in a formula III;
step two: carrying out benzyl protection on hydroxyl of the compound in the formula III to obtain a compound in a formula IV;
step three: deprotecting the amino protecting group of the compound of formula IV to obtain a compound of formula V;
step four: carrying out condensation reduction reaction on the compound shown in the formula V and (2R,2S,4S,5S) -5-hydroxy-2, 3, 4-tri (benzyloxy) -5- [ (benzyloxy) methyl ] -cyclohexanone to obtain a compound shown in a formula VI;
step five: deprotection of a hydroxyl protecting group of the compound shown in the formula VI and salification are carried out to obtain voglibose impurity I hydrochloride; the overall reaction flow is:
2. the preparation method of voglibose impurity I hydrochloride according to claim 1, wherein in step two, the hydroxyl group of the compound of formula III is benzyl-protected under basic conditions to obtain the compound of formula IV.
3. The method for preparing voglibose impurity I hydrochloride according to claim 2, wherein the base used in step two is potassium hydroxide or sodium hydroxide.
4. The method for preparing voglibose impurity I hydrochloride according to claim 2, wherein in step two, the hydroxyl protecting reagent used is benzyl chloride or benzyl bromide.
5. The preparation method of voglibose impurity I hydrochloride according to claim 1, characterized in that in step three, the amino protecting group of the compound of formula IV is deprotected under the action of an acid to obtain the compound of formula V.
6. The method for preparing voglibose impurity I hydrochloride according to claim 5, wherein in step three, the acid used is trifluoroacetic acid or hydrochloric acid.
7. The method for preparing voglibose impurity I hydrochloride according to claim 1, wherein in step four, the reducing agent used is sodium cyanoborohydride.
8. The preparation method of voglibose impurity I hydrochloride according to claim 1, characterized in that, in step five, the hydroxyl protecting group of the compound of formula VI is subjected to catalytic hydrogenation deprotection to form a salt, so as to obtain voglibose impurity I hydrochloride.
9. The method for preparing voglibose impurity I hydrochloride according to claim 8, wherein in step five, the catalyst used is palladium on carbon.
10. The method for preparing voglibose impurity I hydrochloride according to claim 8, wherein in step five, the salifying agent is hydrogen chloride gas.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910880204.1A CN110511152B (en) | 2019-09-18 | 2019-09-18 | Preparation method of voglibose impurity I hydrochloride |
| JP2020155508A JP6852215B2 (en) | 2019-09-18 | 2020-09-16 | Method for preparing voglibose impurity I hydrochloride |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910880204.1A CN110511152B (en) | 2019-09-18 | 2019-09-18 | Preparation method of voglibose impurity I hydrochloride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110511152A CN110511152A (en) | 2019-11-29 |
| CN110511152B true CN110511152B (en) | 2020-11-03 |
Family
ID=68631251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910880204.1A Active CN110511152B (en) | 2019-09-18 | 2019-09-18 | Preparation method of voglibose impurity I hydrochloride |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP6852215B2 (en) |
| CN (1) | CN110511152B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021090884A (en) * | 2021-03-19 | 2021-06-17 | 株式会社三洋物産 | Game machine |
| JP2021090881A (en) * | 2021-03-19 | 2021-06-17 | 株式会社三洋物産 | Game machine |
| JP2021090880A (en) * | 2021-03-19 | 2021-06-17 | 株式会社三洋物産 | Game machine |
| JP2021090879A (en) * | 2021-03-19 | 2021-06-17 | 株式会社三洋物産 | Game machine |
| JP2021090882A (en) * | 2021-03-19 | 2021-06-17 | 株式会社三洋物産 | Game machine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3166093D1 (en) * | 1981-01-05 | 1984-10-18 | Takeda Chemical Industries Ltd | N-substituted pseudo-aminosugars, their production and use |
| WO1999050217A1 (en) * | 1998-03-31 | 1999-10-07 | Bayer Aktiengesellschaft | Valiolone, a method of preparing it, and its use to prepare acarbose and voglibose |
| AU2002344083A1 (en) * | 2002-03-27 | 2003-10-08 | Sawai Pharmaceutical Co., Ltd. | Process for preparation of voglibose |
| CN102050846B (en) * | 2009-11-02 | 2013-09-11 | 上海天伟生物制药有限公司 | Amino sugar, and preparation method and use thereof |
| CN103588650A (en) * | 2012-08-15 | 2014-02-19 | 中国医药集团总公司四川抗菌素工业研究所 | High-purity voglibose and preparation method thereof |
-
2019
- 2019-09-18 CN CN201910880204.1A patent/CN110511152B/en active Active
-
2020
- 2020-09-16 JP JP2020155508A patent/JP6852215B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110511152A (en) | 2019-11-29 |
| JP2021046395A (en) | 2021-03-25 |
| JP6852215B2 (en) | 2021-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110511152B (en) | Preparation method of voglibose impurity I hydrochloride | |
| CA2315262C (en) | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors | |
| JPS5943459B2 (en) | N-alkylpiperidine derivative | |
| CN115286521A (en) | Synthesis method of levosalbutamol hydrochloride | |
| AU2017376363B2 (en) | Class of bifunctional compounds with quaternary ammonium salt structure | |
| CN103804267B (en) | A kind of synthesis technique of vildagliptin | |
| CN108640884B (en) | 2-morpholinone salt, preparation method thereof and preparation method of 2-morpholinone | |
| CN110818581A (en) | Post-treatment method of Sacubitril valsartan sodium intermediate | |
| CN114213285A (en) | Formoterol related substance, preparation method and application thereof | |
| CN103159633A (en) | Preparation method of tapentadol hydrochloride and compounds for preparation of tapentadol hydrochloride | |
| CN114181117A (en) | Preparation method of peramivir intermediate | |
| EP2851363A1 (en) | Agomelatine acid radical composite, and preparation method and application thereof | |
| CN106117104B (en) | A kind of preparation method of vildagliptin | |
| CN107935865A (en) | The preparation method of Miglitol intermediate 1 deoxidation 1 (2 hydroxyethylamino) D glucitols | |
| CN113024405A (en) | Novel lacosamide impurity and preparation method and application thereof | |
| KR20210073972A (en) | A new process for the preparation of (R)-2-((4-Aminophenethyl)amino)-1-phenylethanol | |
| CN113105344B (en) | Preparation method of high-purity aminosugar medicine impurity | |
| CN113248415B (en) | Preparation method of ABT-737 key intermediate and preparation method of ABT-737 | |
| CN113105343B (en) | Preparation method of high-purity aminosugar medicine impurity | |
| CN111662186B (en) | Crystal form of salt formed by bromhexine and fumaric acid and preparation method thereof | |
| CN114805097B (en) | Synthesis method of desmethylvenlafaxine and succinate thereof | |
| CN110872292B (en) | A route for synthesizing linagliptin as diabetes medicine | |
| CN107746385A (en) | A kind of preparation method of Miglitol | |
| CN119192003A (en) | A method for preparing impurities of phenylephrine hydrochloride intermediate | |
| CN1736977B (en) | crystallized (+)-(1S,2S,3S,4R,5R)-1-amido-5-hydroxymethyl-N-2(1,3-dihydroxypropyl)-2,3,4-cyclohexanetriol and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |